| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3025 | 2017 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 329 | 2022 |
| PD-1 blockade in advanced adrenocortical carcinoma N Raj, Y Zheng, V Kelly, SS Katz, J Chou, RKG Do, M Capanu, D Zamarin, ... Journal of Clinical Oncology 38 (1), 71-80, 2020 | 168 | 2020 |
| Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set WR Jarnagin Elsevier Health Sciences, 2022 | 155 | 2022 |
| Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated N Raj, E Valentino, M Capanu, LH Tang, O Basturk, BR Untch, PJ Allen, ... Pancreas 46 (3), 296-301, 2017 | 116 | 2017 |
| Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin … JC Yao, J Strosberg, N Fazio, ME Pavel, P Ruszniewski, E Bergsland, ... Annals of Oncology 29, viii467-viii468, 2018 | 91 | 2018 |
| Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan D Reidy-Lagunes, N Pandit-Taskar, JA O'Donoghue, S Krebs, KD Staton, ... Clinical Cancer Research 25 (23), 6939-6947, 2019 | 89 | 2019 |
| Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms JC Yao, J Strosberg, N Fazio, ME Pavel, E Bergsland, P Ruszniewski, ... Endocrine-related cancer 28 (3), 161-172, 2021 | 78 | 2021 |
| Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability N Raj, R Shah, Z Stadler, S Mukherjee, J Chou, B Untch, J Li, V Kelly, ... JCO precision oncology 2, 1-18, 2018 | 64 | 2018 |
| Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug DL Reidy‐Lagunes, B Lung, BR Untch, N Raj, A Hrabovsky, C Kelly, ... The Oncologist 22 (9), 1102-1106, 2017 | 42 | 2017 |
| Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature Medicine 23 (8), 1004-1004, 2017 | 41 | 2017 |
| O6-methylguanine DNA methyltransferase status does not predict response or resistance to alkylating agents in well-differentiated pancreatic neuroendocrine tumors N Raj, DS Klimstra, N Horvat, L Zhang, JF Chou, M Capanu, O Basturk, ... Pancreas 46 (6), 758-763, 2017 | 38 | 2017 |
| Systemic therapies for advanced pancreatic neuroendocrine tumors N Raj, D Reidy-Lagunes Hematology/Oncology Clinics 30 (1), 119-133, 2016 | 33 | 2016 |
| Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review DL Chan, EK Bergsland, JA Chan, R Gadgil, TR Halfdanarson, ... The Oncologist 26 (11), 950-955, 2021 | 31 | 2021 |
| Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone). C Mulvey, NP Raj, JA Chan, RR Aggarwal, P Cinar, TA Hope, K Kolli, ... Journal of Clinical Oncology 37 (4_suppl), 363-363, 2019 | 26 | 2019 |
| Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway P Selenica, N Raj, R Kumar, DN Brown, O Arqués, D Reidy, D Klimstra, ... Molecular Oncology 13 (8), 1684-1692, 2019 | 25 | 2019 |
| Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with … MR Weiser, JF Chou, A Keshinro, WC Chapman, PS Bauer, MG Mutch, ... JAMA Network Open 4 (11), e2133457-e2133457, 2021 | 24 | 2021 |
| The role of 68Ga-DOTATATE positron emission tomography/computed tomography in well-differentiated neuroendocrine tumors: A case-based approach illustrates potential benefits … N Raj, D Reidy-Lagunes Pancreas 47 (1), 1-5, 2018 | 23 | 2018 |
| Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to determine the clinical efficacy of 177Lu-DOTATATE in neuroendocrine tumors L Bodei, N Raj, RK Do, A Mauguen, S Krebs, D Reidy-Lagunes, ... Journal of Nuclear Medicine 64 (4), 567-573, 2023 | 20 | 2023 |
| Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic … JR Eads, TR Halfdanarson, T Asmis, AM Bellizzi, EK Bergsland, A Dasari, ... Endocrine-related cancer 30 (8), 2023 | 16 | 2023 |
